ASCENDIS PHARMA A/S financials
ASCENDIS PHARMA A/S
549300B66JN3W3J8GH73 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €720.1M | €363.6M |
| Cost of sales | €94.9M | €44.3M |
| Gross profit | €625.2M | €319.4M |
| Operating profit (EBIT) | -€136.3M | -€278.8M |
| Finance costs | €206.7M | €100.0M |
| Profit before tax | -€212.7M | -€373.2M |
| Income tax expense | €15.4M | €4.8M |
| Profit for the year | -€228.0M | -€378.1M |
| — attributable to owners | -€228.0M | -€378.1M |
| Total comprehensive income | -€231.6M | -€377.0M |
| Per share | ||
| Basic EPS | €-0.04 | €-0.07 |
| Diluted EPS | €-0.04 | €-0.07 |
| Cash flow statement | ||
| Cash generated from operations | €68.2M | -€299.9M |
| Net cash from operating activities | €53.9M | -€306.2M |
| Net cash from investing activities | -€8.5M | €6.9M |
| Net cash from financing activities | €36.3M | €443.9M |
| Proceeds from borrowings | €0 | €134.2M |
| Repayments of borrowings | €22.0M | €11.4M |
| Net change in cash | €81.7M | €144.6M |
| Balance sheet | ||
| Total assets | €1.30B | €1.18B |
| Non-current assets | €193.6M | €118.6M |
| Property, plant & equipment | €146.5M | €98.7M |
| Intangible assets & goodwill | €3.7M | €4.0M |
| Current assets | €1.11B | €1.06B |
| Inventories | €301.5M | €295.6M |
| Trade & other receivables | €141.3M | €166.3M |
| Cash & equivalents | €616.0M | €559.5M |
| Total equity | -€162.8M | -€105.7M |
| Non-current liabilities | €396.0M | €377.3M |
| Long-term borrowings | €385.3M | €365.1M |
| Current liabilities | €1.07B | €907.9M |
| Short-term borrowings | €57.1M | €33.3M |
| Deferred tax liabilities | €9.6M | €7.3M |
| Derived metrics | ||
| Operating margin | -18.9% | -76.7% |
| Net margin | -31.7% | -104.0% |
| Return on equity | 140.1% | 357.7% |
| Cash conversion ratio | -0.24× | 0.81× |
| Other reported items | ||
| Adjusted Weighted Average Shares | -0.0M | -0.0M |
| Adjustments For Amortisation Expense | €490.0K | €467.0K |
| Adjustments For Decrease Increase In Inventories | -€5.9M | -€86.7M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €15.6M | -€118.6M |
| Adjustments For Depreciation Expense | €17.2M | €17.2M |
| Adjustments For Finance Costs | €206.7M | €100.0M |
| Adjustments For Finance Income | €114.0M | €25.6M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | €0 | €91.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Property Plant and Equipment | €5.3M | €0 |
| Adjustments For Income Tax Expense | €15.4M | €4.8M |
| Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities | €131.0K | -€1.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€10.4M | €27.0M |
| Adjustments For Provisions | €77.6M | €62.0M |
| Adjustments For Sharebased Payments | €116.2M | €95.5M |
| Adjustments For Undistributed Profits of Associates | €16.3M | -€20.1M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€231.6M | -€377.0M |
| Current Contract Liabilities | €4.9M | €936.0K |
| Current Derivative Financial Liabilities | €256.2M | €150.7M |
| Current Prepayments | €33.7M | €28.3M |
| Current Provisions | €166.4M | €99.1M |
| Current Tax Assets Current | €1.8M | €1.8M |
| Current Tax Liabilities Current | €6.4M | €1.2M |
| Decrease Increase Through Tax On Sharebased Payment Transactions | €11.4M | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€25.2M | €22.8M |
| Equity and Liabilities | €1.30B | €1.18B |
| Finance Costs Paid Classified As Operating Activities | €22.9M | €15.2M |
| Finance Income | €114.0M | €25.6M |
| Finance Income Received Classified As Operating Activities | €15.3M | €14.4M |
| Income Taxes Paid Refund Classified As Operating Activities | €6.7M | €5.5M |
| Increase Decrease Through Sharebased Payment Transactions | €116.2M | €95.5M |
| Increase Decrease Through Treasury Share Transactions | €0 | €0 |
| Investments In Associates Accounted For Using Equity Method | €32.5M | €13.6M |
| Issue of Equity | €87.1M | €340.8M |
| Issued Capital | €8.3M | €8.1M |
| Liabilities | €1.47B | €1.29B |
| Noncurrent Contract Liabilities | €1.1M | €5.0M |
| Noncurrent Receivables Due From Related Parties | €0 | €0 |
| Other Adjustments For Noncash Items | -€5.6M | -€27.1M |
| Other Comprehensive Income | -€3.5M | €1.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€3.5M | €1.1M |
| Other Current Liabilities | €58.2M | €68.0M |
| Other Current Receivables | €14.6M | €9.4M |
| Other Noncurrent Receivables | €10.9M | €2.3M |
| Payments To Acquire Or Redeem Entitys Shares | -€17.4M | €0 |
| Proceeds From Exercise of Warrants | €87.1M | €30.5M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €0 | €950.0K |
| Purchase of Treasury Shares | €17.4M | — |
| Research and Development Expense | €303.6M | €307.0M |
| Selling General and Administrative Expense | €457.9M | €291.1M |
| Share Issue Related Cost | — | €19.3M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €16.3M | -€20.1M |
| Trade and Other Current Payables To Related Parties | €0 | €0 |
| Trade and Other Current Receivables Due From Related Parties | €0 | €0 |
Every line item above is a fact tagged in ASCENDIS PHARMA A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.